These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33092211)

  • 1. New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study.
    Aguilar-Palacio I; Rabanaque MJ; Maldonado L; Chaure A; Abad-Díez JM; León-Latre M; Casasnovas JA; Malo S
    Int J Environ Res Public Health; 2020 Oct; 17(20):. PubMed ID: 33092211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Clusters of Adherence to Cardiovascular Risk Reduction Behaviors and Persistence with Medication in New Lipid-Lowering Drug Users. Impact on Healthcare Utilization.
    Malo S; Rabanaque MJ; Maldonado L; Moreno-Franco B; Chaure-Pardos A; Lallana MJ; Rodrigo MP; Aguilar-Palacio I
    Nutrients; 2021 Feb; 13(3):. PubMed ID: 33668726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study.
    Karlsson SA; Hero C; Svensson AM; Franzén S; Miftaraj M; Gudbjörnsdottir S; Eeg-Olofsson K; Eliasson B; Andersson Sundell K
    BMJ Open; 2018 Mar; 8(3):e020309. PubMed ID: 29602853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study.
    Karlsson SA; Hero C; Eliasson B; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottir S; Eeg-Olofsson K; Andersson Sundell K
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1220-1232. PubMed ID: 28799214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers.
    Malo S; Aguilar-Palacio I; Feja C; Menditto E; Lallana MJ; Andrade E; Casasnovas JA; Rabanaque MJ
    Rev Esp Cardiol (Engl Ed); 2018 Jan; 71(1):26-32. PubMed ID: 28473266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.
    Chrispin J; Martin SS; Hasan RK; Joshi PH; Minder CM; McEvoy JW; Kohli P; Johnson AE; Wang L; Blaha MJ; Blumenthal RS
    Clin Cardiol; 2013 Sep; 36(9):516-23. PubMed ID: 23722477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery.
    Lindenauer PK; Pekow P; Wang K; Gutierrez B; Benjamin EM
    JAMA; 2004 May; 291(17):2092-9. PubMed ID: 15126437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice.
    Lindgren P; Borgström F; Stålhammar J; Alemao E; Yin DD; Jönsson L
    Eur J Cardiovasc Prev Rehabil; 2005 Dec; 12(6):530-4. PubMed ID: 16319541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness of Lipid-Lowering Medications on Outcomes after Stroke: Potential Implications of the New-User Design.
    Olaiya MT; Andrew NE; Dalli LL; Ung D; Kim J; Cadilhac DA; Wood P; May J; Clissold B; Kilkenny MF;
    Neuroepidemiology; 2022; 56(5):365-372. PubMed ID: 35863320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.
    Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Chretin S; Yin D; Alemao E; de Pouvourville G
    Atherosclerosis; 2006 Mar; 185(1):58-64. PubMed ID: 16038912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia.
    Perez-Calahorra S; Laclaustra M; Marco-Benedí V; Lamiquiz-Moneo I; Pedro-Botet J; Plana N; Sanchez-Hernandez RM; Amor AJ; Almagro F; Fuentes F; Suarez-Tembra M; Civeira F;
    Atherosclerosis; 2019 May; 284():245-252. PubMed ID: 30827715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.
    Madsen CM; Kamstrup PR; Langsted A; Varbo A; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):255-266. PubMed ID: 31578080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug prescription rates in secondary cardiovascular prevention in old age: Do vulnerability and severity of the history of cardiovascular disease matter?
    van Peet PG; Gussekloo J; den Elzen WP; Blom JW; de Waal MW; de Ruijter W
    Scand J Prim Health Care; 2015; 33(4):260-8. PubMed ID: 26683286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.
    Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.
    Teramoto T; Kawamori R; Miyazaki S; Teramukai S; Mori Y; Okuda Y; Hiramatsu K;
    Clin Exp Hypertens; 2014; 36(4):236-43. PubMed ID: 23865387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-prescription patterns of cardiovascular preventive treatments: a cross-sectional study in the Aragon worker' health study (Spain).
    Aguilar-Palacio I; Malo S; Lallana M; Feja C; González J; Moreno-Franco B; Rabanaque M
    BMJ Open; 2019 Apr; 9(4):e023571. PubMed ID: 30987984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?
    Selak V; Jackson R; Poppe K; Kerr A; Wells S
    N Z Med J; 2018 Oct; 131(1484):19-25. PubMed ID: 30359352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.